Nephrocare Health Services Q1 FY27 Earnings Call — Analysis (NSE: NEPHROPLUS)
NephroPlus reports strong Q1 FY27 with 23.7% revenue growth and 120 bps margin expansion driven by international mix and operating leverage.
Result quality: stable — Steady quarter. Management sentiment: optimistic.
The take
Q1FY27 Revenue ₹282 Cr ( +23.7% YoY ) . New guidance — medium-term revenue growth guid… 15% to 20% . New story: Platform model replication globally .
Results
Revenue ₹282 Cr +23.7% YoY; Adjusted EBITDA ₹65.1 Cr +30.7% with margin 23.1% (+120 bps); active guests 38,262 (+13%).
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹282 Cr | +23.7% | yoy · Q1FY27 |
| Adjusted EBITDA | ₹65.1 Cr | +30.7% | yoy · Q1FY27 |
| Adjusted EBITDA margin | 23.1% | +120 bps | yoy · Q1FY27 |
| Adjusted PAT | ₹37 Cr | +41.7% | yoy · Q1FY27 |
| Adjusted PAT margin | 13.1% | +170 bps | yoy · Q1FY27 |
| Active guests | 38,262 | +13% | yoy · Jun-26 · as of June 2026 vs June 2025 |
| Treatments | 10.3 lakh | +13.3% | yoy · Q1FY27 |
| Revenue per treatment | ₹2,733 | +9.2% | yoy · Q1FY27 |
| International revenue share | 45% | point_in_time · Q1FY27 · of total revenue | |
| Capital expenditure | ₹44 Cr | point_in_time · Q1FY27 · for center acquisitions and growth | |
| Annualized adjusted ROCE | 21% | point_in_time · Q1FY27 | |
| Working AR days | 101 days | -20 days | yoy · Jun-26 · vs 121 days in June 2025 |
Guidance
Medium-term revenue growth guidance retained at 15-20% over next 3-5 years; annual clinic additions of 40-50 in India and 10-15 in Philippines; new country entry every 12-18 months.
What management committed to
- [NephroPlus] maintains its medium-term growth guidance of 15% to 20% [revenue growth] over the next three to five years. — 15% to 20%, next three to five years
- [NephroPlus] intends to add 40 to 50 new clinics in India every year and 10 to 15 new clinics in the Philippines every year. — 40 to 50 in India, 10 to 15 in Philippines, every year
- [NephroPlus] aims to add a new international market every 12 to 18 months. — every 12 to 18 months, every 12 to 18 months
- The first batch of [NephroPlus International Dialysis Academy] (NIDA) will begin training in the third quarter [FY27]. — Q3FY27
- Formal tendering process [in Saudi Arabia] is expected to begin in a couple of months [from August 2026]. — Q3FY27
- [NephroPlus] will not pursue business that does not meet its return thresholds.
Key themes
Platform-driven international expansion and disciplined capacity growth.
How the narrative shifted
- Platform model replication globally: Management positions the India-built operating platform as replicable across countries, enabling profitable international expansion and validating low-cost model.
- International mix-driven margin expansion: Rising share of international revenue (45%) and procurement leverage from platform boost EBITDA margins; lumpy price increases in markets like Philippines and India provide further uplift.
- Capacity-led growth model: Growth depends on adding capacity through clinics and new machines; same-center volume growth limited due to fixed machine cycles, so clinic additions are essential for revenue growth.
- Shift from unorganized to organized dialysis in India: Only ~20% of Indian dialysis is organized; hospitals are incentivized to outsource as dialysis is low-margin for them, but regulatory comfort for standalone clinics is still developing.
- Nurse supply as bottleneck and NIDA academy: Shortage of trained renal nurses constrains international expansion; NIDA academy will create pipeline and structural advantage.
- Saudi Arabia binary tender opportunity: Saudi is a tender market with high potential but binary outcome; investment phase to demonstrate clinical outcomes; tendering timeline uncertain and not fully in company's control.
- Disciplined capital allocation and ROCE focus: Management underscores not chasing value-dilutive projects, exiting underperforming PPPs, and using technology to improve capital efficiency; capex disciplined.
Operational commentary
- Philippines network crossed 50 clinics across 39 cities, becoming second largest dialysis network; added 7 clinics in Q1.
- Saudi Arabia: first clinic operational in Riyadh Hospital in July, home dialysis commenced; medical operator's license obtained; RFI submitted; formal tendering expected in a couple of months.
- Kazakhstan subsidiary incorporated to evaluate Central Asia opportunities.
- India added 19 clinics across PPP, private, and greenfield; deepened Bihar PPP and signed new contract in Tamil Nadu; exited two value-dilutive Uttarakhand PPP clinics.
- Launched NephroPlus International Dialysis Academy (NIDA) to build renal nurse pipeline; first batch to start training in Q3 FY27.
- AI and technology: RFID asset tracking deployed improved capital efficiency; reform.ai for live process compliance audits; second attempt at predictive adverse event algorithm underway.
- AR days improved from 121 to 101 days via digitization and AI; ECL provision stable at ~2-2.5% of revenue.
- Clinical quality: early vascular access program in Andhra Pradesh moved AVF creation from 15% to 30% of guests, reducing early mortality; NephroPlus index live across 29 centres and 2,600 guests.
Analyst Q&A
Q. What is your capex guidance for this year, and can you split it between India and Philippines?
We typically don't give guidance on the capex front. For this quarter we have done about INR44 crores worth of capex... We indicated we intend to open 40 to 50 clinics in India every year, 10 to 15 clinics in Philippines, and a new international market every 12 to 18 months. That is the extent of guidance.
Q. For the rest of the fiscal, should we assume INR3 odd crores loss on the Saudi JV side will continue?
We are not giving any guidance on the loss assumptions for the Saudi... this may fluctuate a bit... as soon as we have visibility on the timeline we will be able to answer more precisely.
Q. Would you split patients between India, Philippines and other markets, and provide same-store sales growth or metrics for the same set of centers over the last 12 months?
We do not want to mention country by country details and go into the micro... we only would be able to discuss at the platform console level.
Research and educational content only. Not investment advice.